Equities

F D C Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

F D C Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)379.25
  • Today's Change7.15 / 1.92%
  • Shares traded52.16k
  • 1 Year change-6.58%
  • Beta0.9289
Data delayed at least 15 minutes, as of Feb 17 2026 09:39 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

FDC Limited is an India-based company, which is principally engaged in the business of manufacturing and trading of pharmaceutical products. The Company is specialized in manufacturing Oral Rehydration Solutions (ORS), energy drinks, antibiotics and ophthalmic therapies. Its products include Albuterol Sulfate, Bromhexine Hydrochloride, Cinnarizine, Flunarizine Dihydrochloride, Flurbiprofen Sodium, Miconazole Nitrate, Timolol Maleate, Amoxycillin + Clavulanic Acid, Rupatadine Fumarate, Salbutamol Sulphate, Kaolin Light/ Pectin, among others. The Company’s product offerings cover an extensive range of categories, including anti-infectives, gastrointestinal treatments, ophthalmic, vitamins, minerals, dietary supplements, cardiovascular solutions, anti-diabetics, respiratory care, gynecology, dermatology and analgesics. Its various brands include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl and Mycoderm.

  • Revenue in INR (TTM)20.78bn
  • Net income in INR2.17bn
  • Incorporated1940
  • Employees6.86k
  • Location
    F D C Ltd142-148, S.V. Road, Jogeshwari (W)MUMBAI 400053IndiaIND
  • Phone+91 2 226739100
  • Fax+91 2 226300614
  • Websitehttps://www.fdcindia.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Gujarat Themis Biosyn Ltd1.59bn477.88m34.47bn221.0072.13--59.5521.644.394.3914.62--------7,209,322.00--30.70--34.3762.7868.0329.9935.51--55.73-----11.2012.12-17.5615.55104.6124.95
Senores Pharmaceuticals Ltd5.89bn1.02bn36.56bn194.0035.42--28.116.2122.4122.41130.31--------30,336,080.00--------58.73--17.48----5.94----85.64--86.17------
Innova Captab Ltd14.97bn1.32bn38.50bn1.95k29.08--21.872.5723.1323.13261.52--------7,676,703.00--10.02--15.0036.2627.208.858.72--12.45----15.0227.2135.9535.69109.94--
Sun Pharma Advanced Research Co Ltd531.36m-2.68bn43.39bn316.00------81.65-8.26-8.261.64--------1,681,519.00---60.53---129.98-4.34-3.83-504.20-168.34---8.82-----5.00-1.3511.55---28.16--
Zota Health Care Ltd4.73bn-726.58m47.68bn519.00------10.08-23.98-23.98157.24--------9,108,992.00---7.79---10.5757.2242.02-15.34-8.01---3.71----62.3225.23-293.08--49.400.00
Supriya Lifescience Ltd7.35bn1.85bn54.19bn515.0029.22--25.657.3723.0523.0591.47--------14,280,700.00--18.45--21.6372.3359.6225.1925.45--129.43--3.5922.1117.4557.8020.6945.94--
F D C Ltd20.78bn2.17bn60.92bn6.86k28.11--21.982.9313.3113.31127.73--------3,030,531.00--11.35--12.9667.9260.8510.4314.75--47.92--6.348.509.42-12.592.1525.37--
Blue Jet Healthcare Ltd10.53bn2.94bn62.03bn491.0021.12--19.635.8916.9316.9360.76--------21,448,020.00--------53.75--27.88----59.81----44.74--86.38------
Shilpa Medicare Ltd14.32bn1.50bn64.42bn898.0042.49--24.044.507.757.7573.87--------15,945,910.00--2.02--2.6170.4760.0710.485.17--4.67--9.8911.717.22145.63-12.9016.09--
Aarti Pharmalabs Ltd18.01bn2.14bn64.44bn2.16k30.14--20.613.5823.5823.58200.27--------8,324,436.00--------53.87--11.87----9.34----14.17--25.59------
Akums Drugs and Pharmaceuticals Ltd42.57bn3.18bn73.06bn7.54k22.97--15.251.7220.7820.78277.93--------5,648,482.00--------41.45--7.63----4.15-----1.44--8,481.07------
Sudeep Pharma Ltd6.17bn1.68bn74.50bn--43.27--40.5612.0815.2415.2455.94------------------63.01--27.56----55.99----9.40--4.19------
Strides Pharma Science Ltd47.26bn5.11bn79.07bn3.30k15.46--10.861.6755.4955.49512.73--------14,315,680.00---0.6014---1.0959.3450.3311.23-1.06--8.50----17.3610.65437.2252.5010.08-22.16
Marksans Pharma Ltd28.03bn3.60bn80.93bn1.35k22.44--17.642.897.967.9661.92--------20,780,450.00--14.15--17.4156.7751.5612.9014.58--20.42--7.7720.4618.2521.3226.6023.7351.57
Procter & Gamble Health Ltd13.49bn2.93bn83.88bn1.33k28.61--26.526.22176.64176.64811.45--------10,169,760.00--------72.49--21.76----806.81----------------
Jeena Sikho Lifecare Ltd-100.00bn-100.00bn85.61bn3.76k--------------------------32.29--40.74--92.07--16.78--------44.5937.8031.1073.7747.62--
Data as of Feb 17 2026. Currency figures normalised to F D C Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

7.47%Per cent of shares held by top holders
HolderShares% Held
ICICI Prudential Asset Management Co. Ltd. (Invt Mgmt)as of 31 Jan 20264.55m2.79%
Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 31 Dec 20254.28m2.63%
Dimensional Fund Advisors LPas of 05 Feb 20261.11m0.68%
Tata Asset Management Pvt Ltd.as of 31 Jan 2026645.62k0.40%
Bandhan AMC Ltd.as of 31 Jan 2026446.99k0.28%
SSgA Funds Management, Inc.as of 05 Feb 2026441.20k0.27%
BlackRock Fund Advisorsas of 06 Feb 2026259.98k0.16%
BlackRock Advisors (UK) Ltd.as of 06 Feb 2026188.49k0.12%
Motilal Oswal Asset Management Co. Ltd.as of 31 Dec 2025170.36k0.11%
ITI Asset Management Ltd. (India)as of 31 Jan 202676.18k0.05%
More ▼
Data from 31 Dec 2025 - 10 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.